What Is Leucovorin Vitamin B
Leucovorin is a reduced form of folate, also called folinic acid, used to rescue cells from the toxic effects of certain chemotherapy drugs and to treat folate deficiency. It is not folic acid but an active form that bypasses metabolic blocks caused by drugs like methotrexate. According to the National Institutes of Health Office of Dietary Supplements, leucovorin is distinct from standard vitamin B9 and is used in specific oncology protocols. Its role in vitamin B therapy centers on supporting DNA synthesis and repair in healthy cells during aggressive treatment regimens.
The global market for leucovorin calcium injection, a common pharmaceutical form, is driven by its use in high-dose methotrexate therapy and other oncology regimens. Companies such as Teva Pharmaceutical Industries and Hospira, a Pfizer company, produce leucovorin formulations for hospital use. The drug is classified as an essential supportive care medication in many chemotherapy protocols, and its demand correlates directly with cancer treatment volumes worldwide.
Medical Uses and Dosage Protocols
Leucovorin is primarily used to reduce the toxic effects of methotrexate after high-dose cancer therapy and to treat megaloblastic anemia when folic acid metabolism is impaired. It is also used as an antidote for trimethoprim-sulfamethoxazole toxicity and in some protocols for colorectal cancer. The dosage varies by indication, with rescue doses often calculated based on methotrexate levels and body surface area, requiring careful monitoring by oncology teams.
Standard Dosing and Administration
For methotrexate rescue, leucovorin is typically administered orally or intravenously starting 24 to 42 hours after the methotrexate infusion, with doses ranging from 15 mg to 25 mg every six hours, depending on the protocol. The National Cancer Institute provides detailed dosing guidelines for leucovorin in its supportive care standards. Administration must be timed precisely to prevent toxicity while allowing the chemotherapy agent to exert its intended effect on cancer cells.
Regulatory and Market Landscape
Leucovorin products are regulated as prescription drugs by the U.S. Food and Drug Administration and equivalent agencies globally. The FDA's approval history for leucovorin calcium injection includes multiple generic approvals, with the latest updates reflecting ongoing demand in hospital settings. The drug is listed on the World Health Organization's Model List of Essential Medicines, underscoring its critical role in global health systems.
Key Manufacturers and Supply Chain
Major manufacturers include Teva Pharmaceutical Industries, Pfizer's Hospira division, and other generic producers supplying leucovorin to hospitals and cancer centers. Supply chain stability for leucovorin is monitored by the FDA and the American Society of Health-System Pharmacists, with shortages occasionally reported for injectable forms. The competitive landscape is shaped by generic drug pricing and hospital procurement practices, with companies like Baxter International also involved in related injectable oncology support products.